Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
A New And Interesting Addition To The Hep C Clinical Pipeline

The race towards an interferon-free hepatitis C treatment continues to heat up, with a newcomer to the clinical pipeline - BioLine Rx's (BLRX) BL-8020.

Published
18 October 2012
From
Seeking Alpha
MSD bemoans slow uptake for hep C drugs

MSD has revealed new data that it says shows new hepatitis C drugs are seeing slow uptake in the UK. Referencing a 2012 report by the UK’s Health Protection Agency, it says these new data - which looks at the prescribing of new oral treatments for chronic hepatitis C (genotype 1) in the UK - show that less than 1 in 100 (or 0.9%*) of eligible patients are receiving these drugs.

Published
17 October 2012
From
Pharma Times
New rapid and point of care hepatitis C tests could be global game changers

Timely screening and diagnosis is critical to the success of new treatments and ultimately to the survival of hepatitis C patients. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) is the first to show that hepatitis C rapid and point of care tests with a quick turnaround time are highly accurate and reliable as conventional first-line laboratory tests.

Published
16 October 2012
From
Medical Xpress
European guidelines on management of mental health for people with hepatitis C published

European investigators have developed a consensus statement on hepatitis C and mental health. Published in the online edition of the Journal of Hepatology, the wide-ranging document assesses evidence

Published
16 October 2012
By
Michael Carter
Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naive

Abbott (ABT) today announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99 percent of treatment-naive (n=77) and 93 percent of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for 12 weeks, based on an observed data analysis.

Published
15 October 2012
From
Abbott press release
HCV Advocates Survey

The Hepatitis/HIV Project of the Treatment Action Group (TAG), an activist-run AIDS/HCV/TB research and policy think tank, has been providing the latest scientific information to support activists working towards universal HCV treatment access. Please take a few minutes and tell us how we can support your current or planned advocacy work in this critical juncture.

Published
15 October 2012
From
Treatment Action Group
Prior Alcohol Consumption Does Not Impair HCV Treatment

For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.

Published
12 October 2012
From
HCV New Drugs Research
More HIV-Positive Patients Receive Organ Transplants

Hospitals are increasingly willing to transplant vital and scarce organs into people who have HIV, a once-unthinkable step now made possible with drug regimens that are helping such patients live longer.

Published
12 October 2012
From
Wall Street Journal
Vitamin D deficiency associated with a poorer response to HCV treatment in HIV/HCV-co-infected patients

Vitamin D deficiency is associated with a poorer response to hepatitis C therapy in people who are co-infected with HIV and hepatitis C, investigators report in the

Published
11 October 2012
By
Michael Carter
Mental Health in Hepatitis C: A European Expert Consensus Statement

European Liver Patients Association (ELPA) invited leading psychologists, psychiatrists and hepatologists to an expert conference in 2011. Martin Schaefer MD and his colleagues reviewed the scientific data and discussed their experience in the treatment of hepatitis C related psychiatric problems. The results were first presented at the EASL conference in Berlin in 2011. Since the conference, the recommendations were refined and updated further to include the new antiviral treatments, and will now be published as a “European Expert Consensus Statement“ in the Journal of Hepatology.

Published
09 October 2012
From
European Liver Patients Association

Filter by country